Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Faricimab (Vabysmo)

Published October 31, 2022

Key Messages

  • CADTH recommends that Vabysmo be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
  • Vabysmo should be covered to treat patients with DME provided that it is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs currently reimbursed by public drug plans for the treatment of adult patients with DME.
  • Vabysmo should only be reimbursed if prescribed by an ophthalmologist with experience managing DME and if the cost of Vabysmo is not more than the least costly anti-VEGF drug covered by the public drug plans for the treatment of DME.